Price T Rowe Associates Inc Biotechnology

Price T Rowe Associates Inc

$869 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARGX Argenx Se	$32.7B	$3.16 Billion 0.36% of portfolio	5,820,547	Q3 2024 Added 3.97%
REGN Regeneron Pharmaceuticals, Inc.	$79.7B	$1.34 Billion 0.15% of portfolio	1,275,303	Q3 2024 Added 36.71%
NVO Novo Nordisk A S	$238B	$1.14 Billion 0.13% of portfolio	9,583,435	Q3 2024 Added 0.84%
ALNY Alnylam Pharmaceuticals, Inc.	$30.6B	$949 Million 0.11% of portfolio	3,451,833	Q3 2024 Reduced 1.04%
INSM Insmed Inc	$9.85B	$918 Million 0.11% of portfolio	12,580,981	Q3 2024 Added 3.43%
VRTX Vertex Pharmaceuticals Inc	$116B	$822 Million 0.09% of portfolio	1,768,010	Q3 2024 Reduced 20.06%
TECH Bio Techne Corp	$2.7B	$753 Million 0.09% of portfolio	9,424,313	Q3 2024 Added 10.54%
BGNE Bei Gene, Ltd.	$20.1B	$606 Million 0.07% of portfolio	2,700,088	Q3 2024 Added 18.8%
LEGN Legend Biotech Corp	$6.72B	$544 Million 0.06% of portfolio	11,165,584	Q3 2024 Reduced 2.82%
PCVX Vaxcyte, Inc.	$5.1B	$510 Million 0.06% of portfolio	4,466,137	Q3 2024 Added 40.75%
BPMC Blueprint Medicines Corp	$5.66B	$498 Million 0.06% of portfolio	5,387,267	Q3 2024 Reduced 8.28%
RNA Avidity Biosciences, Inc.	$2.28B	$488 Million 0.06% of portfolio	10,633,962	Q3 2024 Reduced 2.59%
ASND Ascendis Pharma A/S	$6.94B	$317 Million 0.04% of portfolio	2,121,128	Q3 2024 Added 18.89%
KYMR Kymera Therapeutics, Inc.	$2.41B	$315 Million 0.04% of portfolio	6,645,474	Q3 2024 Added 3.99%
CRNX Crinetics Pharmaceuticals, Inc.	$3.01B	$253 Million 0.03% of portfolio	4,944,757	Q3 2024 Added 12.22%
RVMD Revolution Medicines, Inc.	$5B	$241 Million 0.03% of portfolio	5,313,305	Q3 2024 Added 1.85%
VERA Vera Therapeutics, Inc.	$1.24B	$174 Million 0.02% of portfolio	3,939,109	Q3 2024 Added 8.81%
RARE Ultragenyx Pharmaceutical Inc.	$3.25B	$170 Million 0.02% of portfolio	3,068,654	Q3 2024 Added 2.56%
IONS Ionis Pharmaceuticals Inc	$5.02B	$169 Million 0.02% of portfolio	4,210,172	Q3 2024 Added 7.01%
CYTK Cytokinetics Inc	$4.69B	$167 Million 0.02% of portfolio	3,164,945	Q3 2024 Added 34.2%
ACLX Arcellx, Inc.	$3.88B	$159 Million 0.02% of portfolio	1,900,611	Q3 2024 Added 16.55%
MDGL Madrigal Pharmaceuticals, Inc.	$5.42B	$156 Million 0.02% of portfolio	733,697	Q3 2024 Reduced 14.56%
MLTX Moon Lake Immunotherapeutics	$1.82B	$150 Million 0.02% of portfolio	2,980,249	Q3 2024 Added 16.35%
IDYA Ideaya Biosciences, Inc.	$1.23B	$127 Million 0.01% of portfolio	4,015,298	Q3 2024 Added 7.25%
AGIO Agios Pharmaceuticals, Inc.	$2.99B	$126 Million 0.01% of portfolio	2,832,512	Q3 2024 Added 1.99%
UTHR United Therapeutics Corp	$16.6B	$123 Million 0.01% of portfolio	344,527	Q3 2024 Added 46.66%
SMMT Summit Therapeutics Inc.	$3.92B	$119 Million 0.01% of portfolio	5,439,657	Q3 2024 Added 166.38%
SWTX Spring Works Therapeutics, Inc.	$2.34B	$113 Million 0.01% of portfolio	3,516,418	Q3 2024 Reduced 2.38%
NUVL Nuvalent, Inc.	$3.92B	$111 Million 0.01% of portfolio	1,082,277	Q3 2024 Added 43.51%
AKRO Akero Therapeutics, Inc.	$1.42B	$109 Million 0.01% of portfolio	3,808,359	Q3 2024 Reduced 8.15%
REPL Replimune Group, Inc.	$554M	$108 Million 0.01% of portfolio	9,879,250	Q3 2024 Added 6.96%
CLDX Celldex Therapeutics, Inc.	$1.23B	$97.9 Million 0.01% of portfolio	2,880,365	Q3 2024 Reduced 9.21%
MRNA Moderna, Inc.	$14.5B	$97.6 Million 0.01% of portfolio	1,459,979	Q3 2024 Reduced 8.74%
LBPH Longboard Pharmaceuticals, Inc.	$812M	$97 Million 0.01% of portfolio	2,909,257	Q3 2024 Added 15.97%
ARVN Arvinas, Inc.	$1.21B	$94.9 Million 0.01% of portfolio	3,853,716	Q3 2024 Reduced 3.39%
DYN Dyne Therapeutics, Inc.	$1.55B	$94.7 Million 0.01% of portfolio	2,636,293	Q3 2024 Added 11.42%
KROS Keros Therapeutics, Inc.	$1.39B	$87.9 Million 0.01% of portfolio	1,514,505	Q3 2024 Added 27.49%
DNLI Denali Therapeutics Inc.	$3.28B	$83.6 Million 0.01% of portfolio	2,869,795	Q3 2024 Added 27.24%
KRYS Krystal Biotech, Inc.	$4.57B	$79.8 Million 0.01% of portfolio	438,259	Q3 2024 Reduced 26.97%
XNCR Xencor Inc	$1.42B	$79 Million 0.01% of portfolio	3,929,062	Q3 2024 Reduced 0.84%
CNTA Centessa Pharmaceuticals PLC	$1.58B	$74.8 Million 0.01% of portfolio	4,679,021	Q3 2024 Added 32.54%
HALO Halozyme Therapeutics, Inc.	$6.37B	$72.7 Million 0.01% of portfolio	1,270,521	Q3 2024 Reduced 2.39%
SRRK Scholar Rock Holding Corp	$1.44B	$69.3 Million 0.01% of portfolio	8,654,106	Q3 2024 Added 5.69%
NRIX Nurix Therapeutics, Inc.	$1.07B	$69 Million 0.01% of portfolio	3,068,961	Q3 2024 Added 8.25%
IMCR Immunocore Holdings PLC	$1.42B	$67.2 Million 0.01% of portfolio	2,157,698	Q3 2024 Reduced 23.83%
IGMS Igm Biosciences, Inc.	$283M	$66.4 Million 0.01% of portfolio	4,014,259	Q3 2024 Reduced 1.49%
MRUS Merus N.V.	$1.97B	$64 Million 0.01% of portfolio	1,281,980	Q3 2024 Reduced 7.45%
PRTA Prothena Corp Public LTD CO	$676M	$64 Million 0.01% of portfolio	3,822,434	Q3 2024 Reduced 9.79%
RCKT Rocket Pharmaceuticals, Inc.	$987M	$59.2 Million 0.01% of portfolio	3,207,781	Q3 2024 Added 1.21%
PTGX Protagonist Therapeutics, Inc	$2B	$58.9 Million 0.01% of portfolio	1,309,467	Q3 2024 Added 8.26%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.